Ramosetron + Placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Irritable Bowel Syndrome

Conditions

Irritable Bowel Syndrome

Trial Timeline

Oct 1, 2010 → Aug 1, 2011

NCT ID

NCT01225237

About Ramosetron + Placebo

Ramosetron + Placebo is a approved stage product being developed by Astellas Pharma for Irritable Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01225237. Target conditions include Irritable Bowel Syndrome.

What happened to similar drugs?

6 of 20 similar drugs in Irritable Bowel Syndrome were approved

Approved (6) Terminated (1) Active (14)

✅Ramosetron + PlaceboAstellas PharmaApproved

✅duloxetineEli LillyApproved

✅Bacillus clausii + MetronidazoleSanofiApproved

✅Iberogast® and Iberogast® NBayerApproved

✅LinaclotideIronwood PharmaceuticalsApproved

✅Linaclotide + PlaceboIronwood PharmaceuticalsApproved

🔄YM060 + PlaceboAstellas PharmaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01225237	Approved	Completed	Oct 1, 2010	Aug 1, 2011	Irritable Bowel Syndrome
NCT00918411	Approved	Completed	Jun 1, 2009	Dec 1, 2009	Irritable Bowel Syndrome

Competing Products

20 competing products in Irritable Bowel Syndrome

See all competitors

Product	Company	Stage	Hype Score
linaclotide + placebo	Astellas Pharma	Phase 2	35
YM060 + Placebo	Astellas Pharma	Phase 3	40
Ramosetron + Placebo	Astellas Pharma	Approved	43
YM060	Astellas Pharma	Phase 3	40
YM060 + placebo	Astellas Pharma	Phase 2	35
YM060	Astellas Pharma	Phase 3	40
linaclotide + Placebo	Astellas Pharma	Phase 3	40
Ramosetron	Astellas Pharma	Pre-clinical	26
YM060	Astellas Pharma	Phase 2	35
ONO-2952 + Placebo comparator	Ono Pharmaceutical	Phase 2	27
ONO-2952 + ONO-2952 Matching Placebo	Ono Pharmaceutical	Phase 2	35
duloxetine	Eli Lilly	Approved	43
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)	AbbVie	Phase 3	40
25mg Eluxadoline + 100mg Eluxadoline	AbbVie	Phase 3	47
Eluxadoline + Placebo	AbbVie	Phase 2	42
Placebo + Linaclotide	AstraZeneca	Phase 3	40
Tegaserod	Novartis	Pre-clinical	26
DNK333	Novartis	Phase 2	35
SMS995 + Placebo	Novartis	Phase 1	29
DNK333 + Placebo	Novartis	Phase 2	35